Приказ основних података о документу

dc.creatorŽivković, Irena
dc.creatorMinić, Rajna
dc.creatorDimitrijević, Ljiljana
dc.date.accessioned2021-02-18T10:52:37Z
dc.date.available2021-02-18T10:52:37Z
dc.date.issued2020
dc.identifier.issn2452-3208
dc.identifier.urihttp://intor.torlakinstitut.com/handle/123456789/549
dc.description.abstractImmunoglobulins, either natural or induced, represent powerful means for eliminating microbial threats. For decades, vaccines have been used which function by inducing antibodies for the successful elimination of microbes, preventing disease and mortality. Polyclonal immunoglobulin products from human plasma were used for the first time to treat immune deficiency during the 1950s. Nowadays, the administration of immunoglobulin, either intravenous or subcutaneous, is the cornerstone of the treatment of primary immunodeficiency affecting the humoral immune system. The therapy can help people with weakened or underdeveloped immune system fight off infections. This is also the treatment of choice for certain autoimmune and neurological diseases. The polyclonal antibody preparation consists of both natural antibodies and antigen-induced antibodies and reflects the history of antigen experience of the donor population. Natural antibodies are germline-encoded, polyspecific, low-affinity antibodies that also have a regulatory role in maintaining the immune system homeostasis. Antibody preparations, enriched for certain desired specificities, or hyperimmune human globulins are used for prophylaxis and treatment of infectious diseases with a high mortality rate. It was shown that lymphocytes from survivors of viral infections, without available vaccines, could be used for protective monoclonal antibodies production. This chapter provides insight into the current knowledge of the usage of antibody preparations, efficacy and mechanism of action, with respect to specific diseases, including the treatment of infectious diseases and future prospects.en
dc.publisherBentham Science Publishers
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/172049/RS//
dc.rightsrestrictedAccess
dc.sourceFrontiers in Clinical Drug Research - Anti Infectives
dc.subjectHigh mortality rate infectious diseases therapyen
dc.subjectImmunodeficiencyen
dc.subjectInduced antibodiesen
dc.subjectInflammationen
dc.subjectIVIGen
dc.subjectMonoclonal antibodiesen
dc.subjectNatural antibodiesen
dc.subjectPassive immunotherapyen
dc.subjectSCIGen
dc.subjectSepsisen
dc.titleAntimicrobial immunoglobulin prophylaxis and therapyen
dc.typebookPart
dc.rights.licenseARR
dc.citation.epage205
dc.citation.issue1
dc.citation.other6(1): 165-205
dc.citation.spage165
dc.citation.volume6
dc.identifier.doi10.2174/9789811425745120060007
dc.identifier.scopus2-s2.0-85092736306
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу